|1.||Khan, Masood A: 7 articles (07/2006 - 02/2003)|
|2.||Tsirka, Stella E: 4 articles (01/2012 - 11/2003)|
|3.||Owais, M: 4 articles (10/2005 - 05/2002)|
|4.||Gupta, C M: 4 articles (01/2005 - 03/2000)|
|5.||Dzierzbicka, Krystyna: 3 articles (12/2015 - 01/2009)|
|6.||Shoenfeld, Yehuda: 3 articles (07/2015 - 01/2015)|
|7.||Fridkin, Mati: 3 articles (05/2015 - 01/2005)|
|8.||Owais, Mohammad: 3 articles (05/2007 - 06/2005)|
|9.||Khan, Arif: 3 articles (05/2007 - 06/2005)|
|10.||Zhang, Jie: 3 articles (03/2007 - 01/2002)|
03/01/1986 - "The efficacy of tuftsin, a naturally-occurring immunomodulating peptide, in the prophylaxis of disseminated Candida albicans infections in mice was studied. "
02/01/2006 - "In the present study, we investigated the immunopotentiating activity of the immunomodulator tuftsin for the treatment of dose-dependent susceptible Candida albicans infection in a murine model. "
06/01/1981 - "The fact that these patients suffer from repeated infections points at an in vivo system that parallels the in vitro studies showing tuftsin stimulation of the phagocytic activity of the tissue macrophage and blood granulocyte. "
12/01/1998 - "Patients with a short bowel treated with long term intravenous nutrition have impaired splenic function, reduced tuftsin activity, and an increased risk of infection."
01/01/1994 - "The potential roles of tuftsin in surgery-related infections have been documented using animal models. "
04/01/1989 - "Administration of tuftsin (50 micrograms/mouse) before candidiasis induction with a lethal dose of candida (7x10(8) candida per mouse) improved mouse survival up to 70%, compared with 10% in the control group. "
07/01/2004 - "To resolve the hypothesis, we studied the role of immunomodulator tuftsin against experimental murine candidiasis in temporarily neutropenic Balb/c mice. "
04/01/1989 - "Thus, a model consisting of mice undergoing peritoneal dialysis was developed in order to study the use of tuftsin as a therapeutic drug against peritoneal candidiasis. "
07/01/2004 - "albicans infection clearly enhanced protection against candidiasis, suggesting a prophylactic role of tuftsin in normal and temporarily neutropenic animals."
04/01/1989 - "The potential of tuftsin as a treatment for candidiasis was shown when the infection was induced with a sublethal dose of candida. "
12/01/2014 - "Many reports have described anti-tumor activity of tuftsin to relate with nonspecific activation of the host immune system. "
05/01/2007 - "The efficacies of the free form of ETP, liposomized ETP (Lip-ETP), and tuftsin-bearing liposomized ETP (Tuft-Lip-ETP) formulations were evaluated on the basis of tumor regression, effect on expression level of p53wt and p53mut, and survival of the treated animals. "
01/01/1995 - "The spleen is the primary producer of tuftsin, which can directly or indirectly kill tumor cells or inhibit their growth. "
01/01/1987 - "In contrast, tuftsin did not influence either the induction of elevated plasma proteinase activity or the activity in plasma from animals with established tumors. "
01/01/1987 - "At this dosage, tuftsin prevented spontaneous tumor development. "
08/01/2005 - "The results of the present study demonstrated higher efficacy of tuftsin-loaded Amp B liposomes against experimental murine cryptococcosis, in terms of enhanced survival rate and reduced fungal burden in organs (lungs and brain) of the treated mice. "
10/01/2005 - "Incorporation of amphotericin B in tuftsin-bearing liposomes showed enhanced efficacy against systemic cryptococcosis in leucopenic mice."
|5.||Visceral Leishmaniasis (Kala Azar)
08/01/2012 - "Augmentation of antileishmanial efficacy of miltefosine in combination with tuftsin against experimental visceral leishmaniasis."
02/01/2002 - "Chemotherapeutic efficacy of the amphotericin B (Amp B), which is the drug of choice for treatment of the leishmanial infections (kala-azar) that become resistant to the conventional chemotherapy using antimonials, has been examined in the Leishmania donovani infected hamsters after encapsulating the drug in tuftsin-free as well as tuftsin-bearing liposomes. "
|2.||Amphotericin B (Amphotericin)
|3.||Adenosine Monophosphate (AMP)
|4.||Etoposide (VP 16)
|7.||Staphylococcal Protein A (A, Protein)
|10.||Opioid Peptides (Opioid Peptide)
|2.||Drug Therapy (Chemotherapy)